SK Capital has finalized the sale of three portfolio companies to Siegfried Holding, completing a previously announced divestiture. The deal removes Noramco, Extractas Biosciences, and Purisys from SK Capital's holdings, while the private equity firm maintains ownership of Halo Pharmaceuticals, its finished-dose-form contract development and manufacturing organization with operations throughout the US and Canada.

The divested companies span specialized pharmaceutical sectors. Noramco, based in Wilmington, Delaware, provides supply chain solutions for active pharmaceutical ingredients across North America. Extractas Bioscience, operating from Tasmania, Australia, focuses on agricultural R&D and purification of high-value plant-derived compounds. Athens, Georgia-based Purisys delivers clinical API development services specifically for controlled substances and pharmaceutical reference standards.

The transaction represents SK Capital's continued strategic reshaping of its pharmaceutical portfolio. By retaining Halo Pharmaceuticals while divesting the three other businesses, the firm concentrates on finished-dose-form CDMO capabilities. Siegfried Holding gains complementary assets that expand its presence in pharmaceutical development and manufacturing, particularly in API and specialized compound handling across North America and Australia.